Clinics in Dermatology
Volume 24, Issue 4 , Pages 256-259 , July 2006

Skin manifestations in acromegaly

References 

  1. Melmed S, Kleinberg D. Anterior pituitary. In:  Larsen PR,  Kronenberg HM,  Melmed S,  Polonsky KS editor. Williams textbook of endocrinology. 10th ed.. Philadelphia (Pa): Saunders; 2003;p. 177–279
  2. Parkinson C, Drake WM, Wieringa G, et al. Serum lipoprotein changes following IGF-I normalization using a growth hormone receptor antagonist in acromegaly. Clin Endocrinol (Oxf). 2002;56:303–311
  3. Fairfield WP, Sesmilo G, Katznelson L, et al. Effects of a growth hormone receptor antagonist on bone markers in acromegaly. Clin Endocrinol (Oxf). 2002;57:385–390
  4. Molitch ME. Clinical manifestations of acromegaly. Endocrinol Metab Clin North Am. 1992;21:597–614
  5. Tavakkol A, Elder JT, Griffiths CE, et al. Expression of growth hormone receptor, insulin-like growth factor 1 (IGF-1) and IGF-1 receptor mRNA and proteins in human skin. J Invest Dermatol. 1992;99:343–349
  6. Lobie PE, Breipohl W, Lincoln DT, et al. Localization of the growth hormone receptor/binding protein in skin. J Endocrinol. 1990;126:467–471
  7. Oakes SR, Haynes KM, Waters MJ, et al. Demonstration and localization of growth hormone receptor in human skin and skin fibroblasts. J Clin Endocrinol Metab. 1992;75:1368–1373
  8. Deplewski D, Rosenfield RL. Growth hormone and insulin-like growth factors have different effects on sebaceous cell growth and differentiation. Endocrinology. 1999;140:4089–4094
  9. Matsuoka LY, Wortsman J, Kupchella CE, et al. Histochemical characterization of the cutaneous involvement of acromegaly. Arch Intern Med. 1982;142:1820–1823
  10. Lange M, Thulesen J, Feldt-Rasmussen U, et al. Skin morphological changes in growth hormone deficiency and acromegaly. Eur J Endocrinol. 2001;145:147–153
  11. Braham C, Betea D, Pierard-Franchimont C, et al. Skin tensile properties in patients treated for acromegaly. Dermatology. 2002;204:325–329
  12. Nabarro JD. Acromegaly. Clin Endocrinol (Oxf). 1987;26:481–512
  13. Jadresic A, Banks LM, Child DF, et al. The acromegaly syndrome. Relation between clinical features, growth hormone values and radiological characteristics of the pituitary tumours. Q J Med. 1982;51:189–204
  14. Centurion SA, Schwartz RA. Cutaneous signs of acromegaly. Int J Dermatol. 2002;41:631–634
  15. Hofeldt FD, Levin SR, Schneider V, et al. Clinical features of acromegaly and response to cryohypophysectomy. Rocky Mt Med J. 1973;70:21–24
  16. Tyrrell JB, Wilson CB. Pituitary syndromes. In:  Friesen SR editors. Surgical endocrinology clinical syndromes. Philadelphia: J.B. Lippincott; 1978;p. 304–324
  17. Letter: skin tags in diabetes mellitus. N Engl J Med. 1976;295:172–173
  18. Tompkins RR. Skin tags and diabetes. Arch Dermatol. 1977;113:1463
  19. Crook MA. Skin tags and the atherogenic lipid profile. J Clin Pathol. 2000;53:873–874
  20. Bhansali A, Kochhar R, Chawla YK, et al. Prevalence of colonic polyps is not increased in patients with acromegaly: analysis of 60 patients from India. J Gastroenterol Hepatol. 2004;19:266–269
  21. Leavitt J, Klein I, Kendricks F, et al. Skin tags: a cutaneous marker for colonic polyps. Ann Intern Med. 1983;98:928–930
  22. Brendler SJ, Watson RD, Katon RM, et al. Skin tags are not a risk factor for colorectal polyps. J Clin Gastroenterol. 1989;11:299–302
  23. Piette AM, Meduri B, Fritsch J, et al. Do skin tags constitute a marker for colonic polyps? A prospective study of 100 asymptomatic patients and metaanalysis of the literature. Gastroenterology. 1988;95:1127–1129
  24. Stone OJ. Acanthosis nigricans—decreased extracellular matrix viscosity: cancer, obesity, diabetes, corticosteroids, somatotrophin. Med Hypotheses. 1993;40:154–157
  25. Downs AM, Kennedy CT. Somatotrophin-induced acanthosis nigricans. Br J Dermatol. 1999;141:390–391
  26. Stals H, Vercammen C, Peeters C, et al. Acanthosis nigricans caused by nicotinic acid: case report and review of the literature. Dermatology. 1994;189:203–206
  27. Mellor-Pita S, Yebra-Bango M, Alfaro-Martinez J, et al. Acanthosis nigricans: a new manifestation of insulin resistance in patients receiving treatment with protease inhibitors. Clin Infect Dis. 2002;34:716–717
  28. Todd DJ, Eedy DJ, McMillan JC. Acromegaly and psoriasis. Clin Exp Dermatol. 1991;16:222–223
  29. Weber G, Klughardt G, Neidhardt M, et al. Treatment of psoriasis with somatostatin. Arch Dermatol Res. 1982;272:31–36
  30. Weber G, Neidhardt M, Frey H, et al. Treatment of psoriasis with bromocriptine. Arch Dermatol Res. 1981;271:437–439
  31. Weber G, Klughardt G, Neidhardt M. Psoriasis and human growth hormone: aetiology and therapy. Arch Dermatol Res. 1981;270:361–365
  32. Valentino A, Fimiani M, Bilenchi R, et al. Therapy with bromocriptine and behavior of various hormones in psoriasis patients. Boll Soc Ital Biol Sper. 1984;60:1841–1844
  33. Venier A, De Simone C, Forni L, et al. Treatment of severe psoriasis with somatostatin: four years of experience. Arch Dermatol Res. 1988;280(Suppl):S51–S54
  34. Schiavon F, Maffei P, Martini C, et al. Morphologic study of microcirculation in acromegaly by capillaroscopy. J Clin Endocrinol Metab. 1999;84:3151–3155
  35. Maison P, Demolis P, Young J, et al. Vascular reactivity in acromegalic patients: preliminary evidence for regional endothelial dysfunction and increased sympathetic vasoconstriction. Clin Endocrinol (Oxf). 2000;53:445–451

PII: S0738-081X(06)00052-6

doi: 10.1016/j.clindermatol.2006.04.011

Clinics in Dermatology
Volume 24, Issue 4 , Pages 256-259 , July 2006

Article Tools

* Image Usage & Resolution